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Hepatocyte-like cells derived from the differentiation of human
embryonic stem cells (hES-Hep) have potential to provide
a human relevant in vitro test system in which to evaluate the
carcinogenic hazard of chemicals. In this study, we have
investigated this potential using a panel of 15 chemicals classiﬁed
as noncarcinogens, genotoxic carcinogens, and nongenotoxic
carcinogens and measured whole-genome transcriptome responses
with gene expression microarrays. We applied an ANOVA model
that identiﬁed 592 genes highly discriminative for the panel of
chemicals. Supervised classiﬁcation with these genes achieved
a cross-validation accuracy of > 95%. Moreover, the expression of
the response genes in hES-Hep was strongly correlated with that
in human primary hepatocytes cultured in vitro. In order to infer
mechanistic information on the consequences of chemical
exposure in hES-Hep, we developed a computational method
that measures the responses of biochemical pathways to the panel
of treatments and showed that these responses were discriminative
for the three toxicity classes and linked to carcinogenesis through
p53, mitogen-activated protein kinases, and apoptosis pathway
modules. It could further be shown that the discrimination of
toxicity classes was improved when analyzing the microarray data
at the pathway level. In summary, our results demonstrate, for the
ﬁrst time, the potential of human embryonic stem cell–derived
hepatic cells as an in vitro model for hazard assessment of
chemical carcinogenesis, although it should be noted that more
compounds are needed to test the robustness of the assay.
Key Words: carcinogenicity; systems toxicology; risk
assessment; toxicogenomics; computational biology.
The inherent capacity of human embryonic stem cells
(hESC) to grow indeﬁnitely and to differentiate into all mature
cell types of the body makes them extremely attractive for
toxicity testing and other applications, such as regenerative
medicine, tissue engineering, and drug discovery (Thomson et al.,
1998). Although a few factors still limit the general implementa-
tion of pluripotent stem cells for clinical applications, their
opportunities for use in predictive in vitro a s s a y sa r ei m m e n s ea n d
fuel further developments of improved cellular models that may
increase their relevance for the human situation in vivo and reduce
the need of experimental animals in testing of drugs, cosmetics,
and other chemical compounds (Jensen et al.,2 0 0 9 ).
To improve the assessment of the carcinogenic hazard (and
ultimately the risk) due to the exposure to chemicals is
a major challenge to public health and customer’s safety. It
has been addressed in Europe within the Registration,
Evaluation, Authorization and Restriction of Chemicals
(REACH) initiative aiming to assess toxicity of an estimated
number of 68,000 chemicals (Hartung and Rovida, 2009).
Until now, the majority of tests are based on in vivo assays, in
particular on the 2-year rodent bioassay for carcinogenicity.
Besides the challenge of replacing animal testing (it has been
estimated that full compliance with REACH legislation for all
endpoints of toxicity will require a grand total of 54 million
vertebrate animals and will cost V9.5 billion over the next
decade), it has been argued that the effects of chemical
exposure differ widely in rodents and humans, and this might
lead to a high number of false positive predictions. For
example, cholesterol-lowering drugs, such as atorvastatin,
ﬂuvastatin, and simvastatin among many other pharmaceuti-
cal agents approved as safe drugs for human use by the FDA,
were classiﬁed as rodent carcinogens (Ward, 2008). Thus, it
has been understood that human in vitro assays must be
developed for predicting carcinogenic effects of chemicals in
human more reliably (Vinken et al., 2008).
High-throughput technologies such as microarrays have
opened the way to a systemic understanding of toxicology and
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toxicology approaches offer the chance for disclosing valuable
mechanistic information on toxic modes of action of substances
in the assay system under study, which obviously is promising
in view of the urgent need to develop better (in vitro) tests for
chemical safety. Mechanistic approaches require the analysis of
whole-genome data at the pathway level incorporating
knowledge on human interaction networks (Kitano, 2002;
Wierling et al., 2007). Pivotal for such approaches is the
availability of sufﬁcient information on human pathways,
related to cancer initiation and progression, along with
computational approaches that combine results from high-
throughput experiments with biological networks (Bader et al.,
2006; Kamburov et al., 2011).
The liver appears a major target for the effect of carcinogenic
compounds in the rodent 2-year bioassay. Although recent
reports evidenced the suitability of human carcinoma cell lines
for classiﬁcation of chemicals (Jennen et al., 2010), the
applicability of stem cells for such purpose is still unexplored.
The feasibility of differentiating hESC to hepatic cells (hES-
Hep) using a developmental biology approach (Brole ´n et al.,
2010) has already been shown. In the present work, we
demonstrate the application of a hESC-derived cell assay for
hazard assessment of carcinogenicity with a panel of 15
chemicals from three different toxicity classes (genotoxic
carcinogens [GTX], nongenotoxic carcinogens [NGTX], and
noncarcinogens [NC]) using Affymetrix microarray measure-
ments before and after chemical treatment of the cells. We
applied an ANOVA model that identiﬁed 592 genes highly
discriminative for the assayed chemicals. The expression of
these response genes as well as the expression of Phase I–III
genes derived from hES-Hep is strongly correlated with those
in human primary hepatocytes cultured in vitro demonstrating
the metabolic competence of the system. Supervised classiﬁ-
cation analysis with the response genes, also incorporating
additional data, achieved a cross-validation performance of
> 95%. In order to deduce mechanistic information on the
modes of action of the different compounds in hES-Hep, we
assigned numerical scores based on expression data to 1695
manually annotated human pathways originating from several
pathway resources (Kamburov et al., 2011) that reﬂect the
response of these pathways to the chemicals. Using this
approach, we were able to identify discriminative pathway
modules, both for individual substances and toxicity classes, in
particular in p53, mitogen-activated protein kinase (MAPK),
and apoptosis pathways. Moreover, it was observed that the
discrimination of the toxicity classes was improved when
shifting from the gene to the pathway level analysis of
microarray data.
To summarize, our results demonstrate, for the ﬁrst time, the
potential of hESC-derived hepatocyte-like cells as an in vitro
model for hazard assessment of carcinogenicity of chemical
compounds and open a new application domain for stem cell
research in toxicology.
MATERIALS AND METHODS
Cultures of hESC and differentiated hepatocytes. This study was
performed with the commercially available product hES-Hep002 (Cellartis
AB, Go ¨teborg, Sweden, http://www.cellartis.com). The hESC line SA002 was
derived, cultured, and characterized as previously described (Heins et al., 2004,
2006) with an additional step of enzymatic passage for further expansion before
the onset of differentiation. Characterization and start of compound incubation
were performed at day 22 after the start of hepatic differentiation.
Other liver cellular models. RNA from ﬁve different human liver cell
models was compared with hES-Hep. HepG2 (HB-8065; American Type
Culture Collection, Manassas, VA), human fetal liver polyA þ RNA (Clontech
Laboratories, Inc.), human adult liver tissue, and nonplated and plated adult
human primary hepatocytes (hpHep). All human adult liver samples were
isolated from two different donors and were obtained as described in Brole ´n
et al. (2010). The isolated human hepatocytes were split into two aliquots. One
of these was immediately directed into RNA (nonplated hpHep), and the other
one was cultured 48 h in vitro before RNA was isolated (plated hpHep).
Immunocytochemistry. Cells were ﬁxed in 4% (wt/vol) paraformaldehyde
for 15 min at room temperature, washed twice with PBS, blocked with 5% skim
milk in PBS for 30 min, and then incubated with primary antibody at the
appropriate dilution in PBS with 1% bovine serum albumin (BSA) and 0.2%
Triton X-100 at 4C overnight. After washing with PBS, the secondary
antibody, in PBS with 1% BSA and 0.2% Triton X-100, was applied for 1 h. To
visualize the nucleus, 4#,6-diamidino-2-phenylindole at 0.5 lg/ml was included
during the secondary antibody incubation. The following primary antibodies
were used: rabbit anti-albumin (1:500; Bethyl Lab), mouse anti-a-fetoprotein
(AFP) (1:500; Sigma), mouse anti-cytokeratin (CK18) (1:200; DAKO
Cytomation), rabbit anti-a1-antitrypsine (a1-AT) (1:200; DAKO Cytomation),
rabbit anti-Cyp1A2 (1:100; Biomol), rabbit anti-MRP2 (1:50; Santa Cruz), and
rabbit anti-HNF4a (1:300; Santa Cruz). The following secondary antibodies
were used: Alexa Fluor 488 donkey anti-rabbit (1:1000; Molecular Probes) and
Alexa Fluor 488 donkey anti-mouse (1:1000; Molecular Probes). The cells
were ﬁnally mounted with DAKO ﬂuorescent mounting medium and visualized
and captured using a Nikon Eclipse TE2000-U Fluorescence microscope and
Nikon Act-1C for DXM1 200C software.
RNA extraction, reverse transcription, and quantitative PCR. Cells were
isolated in RNAprotect Cell Reagent (Qiagen), and total RNA was extracted
using RNeasy Plus Mini Kit (Qiagen) according to the manufacturer’s
instructions. Reverse transcription was performed using 0.6 lg of total RNA
in a ﬁnal volume of 20 ll together with reverse transcriptase (Roche
Diagnostics), using a High Capacity cDNA Reverse Transcriptase Kit (Applied
Biosystems) and an Eppendorf Mastercycler Gradient. Each RNA sample was
reverse transcribed in duplicate, and appropriate negative controls were
included in each run. TaqMan real-time quantitative PCR (qPCR) assay-on-
demand primers from Applied Biosystems (ABI) were used for the following
genes: CYP1A2, CYP3A4, CYP2C9, OCT1, OATP2, GSTA1, BCEP, and qPCR
were conducted as previously described by Ek et al. (2007). For validation of
the microarray data, TPD52, TNFAIP3, and PDCD4 were purchased from ABI.
Real-time qPCR was conducted as previously described across the panel of
treatments (Brole ´n et al., 2010).
Cytochrome P450 activity. Cytochrome P450 (CYP) activity assays were
performed by the direct incubation of hES-Hep (day 22) and human primary
hepatocytes (plated for 48 h) in monolayer cultures with a cocktail of substrates,
each one speciﬁc for one CYP enzyme, at following ﬁnal concentrations: 10lM
7-bupropion, 10lMp h e n a c e t i n ,1 0 lMd i c l o f e n a c ,5 lM midazolam, and 50lM
mephenytoin. After 16 h at 37C, the supernatant was collected and metabolites
formed by cells during the incubation were quantiﬁed by HPLC-MS/MS as
described in Donato et al. (2010) and Lahoz et al. (2008).
Compound treatment experiments. Samples were generated by incubat-
ing hES-Hep with 15 compounds of three different toxicity classes that were
chosen from a previously deﬁned body of model compounds causing
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(GTX) were 2-nitroﬂuorene (2NF), benzo[a]pyrene (BAP), 4-(methylnitrosa-
mino)-1-(3-pyridyl)-1-butanone (NNK), aﬂatoxin B1 (AFL), and cyclophos-
phamide monohydrate (CYC); nongenotoxic carcinogens (NGTX) were
methapyrilene hydrochloride (MPH), piperonylbutoxide (PPX), sodium
phenobarbital (SPB), WY-14,643/pirinixic acid (WYE), and tetradecanoyl
phorbol acetate (TPA); NC were sodium diclofenac (DIC), D-mannitol (DMA),
nifedipine (NFE), clonidine hydrochloride (CLO), and tolbutamide (TOL).
Chemicals were obtained from Sigma Chemical Co, Aldrich Chemical
Company. The hES-Hep were incubated with compounds at IC10 concen-
trations for 72 h (Supplementary table 1) and compared with respective control
samples (hES-Hep cultured in media supplemented with 0.5% dimethyl
sulfoxide [DMSO]). Final concentration of DMSO was 0.5% in all cultures and
assays were run in triplicates using three different cell passages.
Determining ﬁnal exposure concentrations based on the MTT
assay. The cytotoxicity of the 15 compounds investigated was assessed using
the MTT assay (reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide), following the manufacturer’s instructions (Sigma) (Supple-
mentary ﬁgure 1A). Dilution series for each of the 15 chemicals were
performed. hESC-derived hepatocyte-like cells cultured in 0.1% gelatin-coated
24-well plates were incubated for 72 h. Incubated cells and controls were
washed in PBS, and the MTT assay was started by adding 0.4 ml per well of
MTT reagent, dissolved in PBS and diluted to 0.5 mg/ml in phenol red–free
media, and incubated for 1 h at 37C. The supernatants were collected, and the
spectrophotometric absorbance was read at 550 nm. From these absorbance
data, IC10 at 72 h was calculated and determined with the GraphPad Prism 5
software. The MTT curves displayed data from maximum achievable
concentration to zero and were repeated 3–5 times with cells from different
passages for each concentration and for all 15 compounds.
Microarray data generation. Target preparation and microarray hybrid-
ization of the Affymetrix Human Genome U133 Plus 2.0 GeneChip arrays were
performed by standard methods as described in Jennen et al. (2010). The arrays
were scanned by means of an Affymetrix GeneArray scanner. Normalization
quality controls, including scaling factors, average intensities, present calls,
background intensities, noise, and raw Q values, were within acceptable limits
for all chips. Hybridization controls, BioB, BioC, BioD, and CreX, were called
present on all chips and yielded the expected increases in intensities.
Gene expression analysis. Raw microarray data was remapped to the
Ensembl version 55 genome build as previously described in Dai et al. (2005).
Data was preprocessed with the GC-RMA method. For each gene in each
exposure experiment, we computed its detection p value indicating the strength
of gene expression and its fold change (log base 2) based on the average values
of the three treatments and the three control experimental replicates. Fold
changes for all chemical treatments were analyzed with a one-way ANOVA
model in order to identify a response gene set that is able to discriminate
between the three compound classes. The signiﬁcance of variance ratios was
quantiﬁed with the F statistic (p value < 0.05). Additionally, we computed
a one-sample Student’s t-test (p value < 0.05) to judge whether the gene’s fold
changes were consistent within the same toxicity class.
Pathway response analysis. As pathway resource, we used the Con-
sensusPathDB (Kamburov et al., 2011; http://cpdb.molgen.mpg.de), a meta-
database that integrates the content of 22 different interaction databases and that
comprises 2144 predeﬁned human pathways, of which 1695 had more than ﬁve
members and were used for pathway response analysis. We computed
a response score Sij for each gene i in each treatment experiment j by
Sij ¼
 log2

Rij
 3
 log10

Pij
 ;
where Rij and Pij are the fold change and the p value, respectively, of gene i
when comparing the treatment j microarray replicates against their control
replicates. The score for each pathway is the average score derived from all
scores of genes assigned to the pathway. In order to make the raw pathway
response scores comparable across different treatment experiments, we
computed the log2 ratios of the pathway response scores for a particular
treatment and the median score of that treatment.
Cross-validation analysis. We used supervised classiﬁcation and follow-up
cross-validation in order to challenge the response gene set with the problem of
classifying chemicals according to the toxicity classes. The analysis was done
with a support vector machine with a linear kernel and a penalty factor of 10. To
assess the misclassiﬁcation rates, we used the Leaving-One-Out (LOO) method
by removing and subsequent classiﬁcation of single compound patterns.
RESULTS
Liver Characteristics of hES-Hep
Differentiation of hESC into hepatocyte-like cells was
carried out as described in ‘‘Materials and Methods’’. The
hES-Hep were grown at day 22 after the onset of differentiation
in homogenous cultures in monolayer displaying a typical
hepatic morphology (Fig. 1A) and were positive for important
hepatocyte markers and liver-related proteins. For example, a1-
AT, AFP, ALB, CK18,a n dHNF4a were expressed along with
CYP1A2 and visualized by immunocytochemistry (ICC) (Fig. 1B).
Hepatic phase I enzymes (CYP1A2, CYP3A4,a n dCYP2C9),
phase II enzyme (GSTa1), and phase III transporter proteins
(OCT1, OATP2,a n dBCEP) were detected on mRNA level by
real-time qPCR (Fig. 1C). Additionally, results from the CYP
activity measurements conﬁrmed the presence of functional
enzymatic activity of the most important hepatic CYP enzymes
(CYP1A2, CYP3A4, CYP2B6, CYP2C9,a n dCYP2C19; Fig. 1D)
in comparison with hpHep.
Microarray data from untreated hES-Hep gave insights into
the transcriptome of the cells. Remapping of oligoprobes
yielded 18,394 Ensembl-annotated genes with sufﬁcient
uniquely mapped probe sequences. Of these, 8745 genes
(47.54%) were found expressed in hES-Hep (detection p value
< 0.01). In addition, 2976 genes were expressed at a lower
level (detection p value between 0.01 and 0.1). The actual
number of expressed genes in hES-Hep relates to published
estimates of gene expression in human hepatocytes found
with other technologies. For example, 7475 genes were
previously found expressed in human hepatocytes on the basis
of public expressed sequence tag data (Huang et al., 2007).
Among the expressed genes, we found hepatocyte markers
such as CD44, TM4SF1, DPP4, SERPINA1/a1-AT, ALB, TF,
FOXA2, CYP3A5, HNF4a, CYP1A1, AFP, ABCC2, SER-
PINA7, GSTA1, KRT19, CYP3A4, and CYP2B6. Several
markers that were tested for hepatocyte-like characteristics of
the cells were not detected with microarrays including SLCO1B1,
CYP2C9, ADH1C, CYP1A2, SLC22A1, CYP3A7, ABCB4, TAT,
and CYP7A1 (Fig. 1E). These genes were either not expressed in
the cells, expressed at a level below the detection limit of
microarrays, or were not annotated after remapping of the
oligoprobes. For example, cytokeratin 18 (CK18) is a hepatic
marker that was clearly visible in the ICC screens (cf. Fig. 1B)
but was excluded from microarray annotation because of absence
of uniquely mappable oligoprobes.
280 YILDIRIMMAN ET AL.FIG. 1. Hepatocyte-like characteristics of hES-Hep. (A) Phase contrast microscopy demonstrating the typical hES-Hep morphology after 22 days of differentiation.
(B) Cells were positive for hepatocyte markers, such as a1-AT, AFP, albumin, CK18, HNF4a,a n dCYP1A2. (C) qPCR gene expression of hES-Hep show an expression
of CYP1A2, CYP3A4, CYP2C9, OCT1, OATP2, GSTA1,a n dBCEP in comparison with HepG2 and undifferentiated hESC. Y-axis shows log2 values relative to HepG2
and hESC (n ¼ 4). (D) CYP activity of CYP1A2, CYP3A4, CYP2C9, CYP2C19,a n dCYP2B6 further supporting that these cells are hepatocyte-like. Y-axis scale is
Pmoles total log2 (n ¼ 3). hpHep ¼ human primary hepatocytes cultured for 48 h. (E) Signiﬁcance of gene expression of hepatic markers in untreated hES-Hep. Y-axis
displays the negative log10 of the detection p values of the gene expression signals. Horizontal lines indicate the 0.1 (orange) and 0.01 (red) detection levels.
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Ashburner et al., 2000) in order to characterize the functional
content of the gene expression in hES-Hep. Interestingly, 4148
(47%) of the expressed genes were associated with ‘‘metabolic
processes’’ underlining the high level of metabolic competence
of the cells. Closer investigation of the genes associated with
drug metabolism yielded gene expression of important phase
I, II, and III genes (Supplementary table 2). Although there was
fairly consistent expression of phase II and III genes across the
panel of treatments, higher variability was observed in
cytochrome P450 enzyme expression in particular with the
CYP2 family, which is known as a heterogeneous group of
enzymes with highly variable substrate speciﬁcities (Nelson
et al., 1996).
Identiﬁcation and Characterization of Response Genes
The study design of chemical treatments with the hES-Hep is
described in Supplementary ﬁgure 1B.W eu s e da nA N O V A
model (‘‘Materials and Methods’’) that identiﬁed 592 response
genes with signiﬁcant variation among the three toxicity classes
(F test p value < 0.05; Supplementary table 3). These genes
achieved a high level of discrimination according to the three
toxicity classes (Fig. 2A). The major proportion of response
genes was associated with metabolic processes (234 of 592). A
GO characterization is visualized in Supplementary ﬁgure 2.
In order to functionally interpret the gene response, we
performed overrepresentation analysis using the Consensus-
PathDB. Eleven pathways were found overrepresented (Fisher
test p value < 0.05; Table 1) monitoring a signiﬁcant
genotoxic response in particular with ATM and p53 pathway
modules. This result suggests that the selected gene set
contains a large proportion of genes that act in the interplay
of DNA damage response, p53 signaling, and apoptosis.
Selective validation of microarray results was performed with
qPCR as is shown for PDCD4 (Fig. 2B), TNFAIP3 (Fig. 2C),
and TPD52 (Fig. 2D). These genes are involved in
pathological apoptotic process e si nh u m a na n dw e r es i g n i f -
icantly altered in genotoxic treatments in qPCR as well as
microarray experiments (Fig. 2E). For example, downregula-
tion of the tumor suppressor PDCD4 on the protein level and
its pro-apoptotic effects for TGF-b1-induced apoptosis has
been shown previously in human hepatocellular carcinoma
(Zhang et al., 2006).
The ultimate purpose of the response gene set is to
discriminate chemicals capable of triggering carcinogenesis
in vivo; thus, it is particularly important to analyze the response
of tumor suppressor genes and oncogenes because in vivo
carcinogenesis is a complex process that is driven by tight
interactions between oncogene activation, tumor suppressor
inactivation, and the cell death machinery (Zhivotovsky and
Orrenius, 2010). Among the 592 genes, we found eight tumor
suppressors (PDCD4, BCL2, SMAD3, FHIT, ATM, TCHP,
ITGB5,a n dRPL10) and ﬁve oncogenes (RAB17, RRAS, FAS,
MDM2,a n dGNA15). Mechanisms relating to these genes have
been shown previously in the literature, for example, the
activation of MDM2 by the downregulation of the tumor
suppressor FHIT (Schlott et al.,1 9 9 9 ). Downregulation of FHIT
and upregulation of MDM2 was observable in four of the ﬁve
genotoxic treatments (AFL, BAP, NNK, and CYC), whereas
such effects were much weaker or not visible with the
nongenotoxic and noncarcinogenic treatments. These ﬁndings
are consistent with recent results from rodent studies, for
example, from primary rat hepatocytes (Mathijs et al.,2 0 0 9 ),
where Mdm2 has also been prominently identiﬁed as discrim-
inating between genotoxic and nongenotoxic compounds.
Performance of hES-Hep as a Hazard Assessment Assay
In order to test the potential of hES-Hep for classifying
carcinogenic substances, we applied supervised classiﬁcation
with a support vector machine approach and compared
performance of the response gene set (N ¼ 592) with the
genome-wide approach (N ¼ 18,394). Misclassiﬁcation rates
were computed with a cross-validation procedure (LOO).
Additional data was introduced using the same 15 treatments at
a lower time point (IC10 at 24 h, see ‘‘Materials and
Methods’’) and a subset of nine of the compounds also with
lower concentrations (50% of the IC10 at 24 h and 72 h). The
misclassiﬁcation rate using all data (in total, 15 þ 15 þ 9 þ 9
¼ 48 experiments) was 6.25% with whole-genome data and
dropped to 4.17% with the response genes as readouts
(Table 2).
Comparison of Response Gene Expression in hES-Hep and
Other Liver Cellular Models
We compared the expression patterns of the 592 response
genes with Affymetrix microarray data on other liver-like
cellular models. Pearson correlation of the gene expression in
hES-Hep was 0.88 as compared with plated primary human
hepatocytes, 0.83 as compared with HepG2 cells, 0.80 as
compared with human fetal liver, 0.79 as compared with human
adult liver, and 0.76 as compared with nonplated primary human
hepatocytes (Table 3A). The result points to the fact that the
expression of the response genes in hES-Hep highly resembled
human hepatic cell systems and was also similar to HepG2 that
is a widely used in vitro hazard assessment system. Moreover,
correlation of hES-Hep to the other liver systems was even
slightly higher than that of HepG2 in all cases. Furthermore, we
computed correlation of gene expression of 78 selected Phase
I, II, and III genes (cf. Supplementary table 2) and found
a signiﬁcant correlation of hES-Hep with primary plated
hepatocytes (0.71) and HepG2 (0.79, plots not shown).
Additionally, we have examined whether the expression
signals of the response genes in hES-Hep upon carcinogenic
treatments (GTX and NGTX compounds) resemble expression
patterns in human liver cancer and incorporated publicly
available data (GSE29722) on 10 human liver tumors
(Stefanska et al., 2011). The correlation of expression patterns
with human liver tumor data was 0.80 for the GTX treatments
282 YILDIRIMMAN ET AL.FIG. 2. Response genes. (A) Principal component analysis (PCA) with the 592 response genes. Different compound classes are indicated by colors (red ¼
genotoxic carcinogens (GTX), blue ¼ nongenotoxic carcinogens (NGTX), and green ¼ noncarcinogens (NC)). The two principal components explain 66.2% of the
variance (PC1: 56.58%; PC2: 9.595%). PCA was generated with the J-Express 2009 software (MolMine AS, Bergen, Norway). qPCR validation of (B) PDCD4,
(C) TNFAIP3, and (D) TPD52 compared with microarray measurements across the panel of substance treatments. Y-axis displays the log2 ratios in treatment
versus control experiments of qPCR (red bars) and microarrays (blue bars). (E) Scatter plot of all 45 log2 ratios. Treatments are displayed with colors (red ¼ GTX,
blue ¼ NGTX, and green ¼ NC); individual genes are displayed with different shapes (square ¼ PDCD4, triangle ¼ TNFAIP3, and circle ¼ TPD52).
hESC TECHNOLOGY FOR PREDICTING CARCINOGENICITY 283and 0.82 for the NGTX treatments, with fairly consistent values
for the individual treatments (Table 3B).
Pathway Responses to Chemical Treatments in hES-Hep
We further aimed to quantify the response of hES-Hep to
chemical treatments at the pathway level (‘‘Materials and
Methods’’) using preannotated pathways with at least ﬁve
members that were measurable with microarray oligoprobes
(1695 of 2144). Global pathway response was highly variable
among the 15 treatments. Seven substances induced a strong
overall response with respect to many of the 1695 pathways
(CYC, CLO, MPH, TOL, BAP, NNK, and TPA), whereas the
remaining substances induced a far lower response (data not
shown). In order to make the pathway response scores
comparable among the different treatments, we divided for
each chemical treatment the scores by the median pathway
score (see ‘‘Materials and Methods’’). Interpretation at the
pathway level can be driven toward several directions. Firstly,
we observed pathway responses distinguishing carcinogenic
(either GTX or NGTX) from noncarcinogenic treatments, for
example, modules from the apoptosis (Student’s t-test p ¼
0.0076) and MAPK (p ¼ 0.0003) signaling pathways (Fig.
3A). This ﬁnding correlates with published results for
genotoxic compounds, for example, for BAP (Chen et al.,
2003). Highest response to MAPK signaling among the NGTX
treatments was observed for WYE, a PPAR-a ligand that is
prototypical for peroxisome proliferators. It has been shown in
primary rat hepatocyte cultures that carcinogenic effects on
proliferation and apoptosis of peroxisome proliferators require
p38 MAP kinase activity (Cosulich et al., 2000), although there
is an ongoing debate whether the carcinogenic effects of
peroxisome proliferators via PPAR-a extrapolate from the
rodent to the human system (Peters, 2008).
Secondly, pathway analysis enables to distinguish low-
responding and high-responding pathway modules for each
toxicity class. High pathway responses among the GTX
treatments were observed for p53 and apoptosis pathway
modules, whereas NGTX treatments exerted their effects
mainly through PI3K/AKT, PPAR, and MAPK signaling
(Fig. 3B). NC treatment responses were less speciﬁc. In order
to identify pathways that appear consistently affected by the
different toxicity classes, we computed for each toxicity class
and each pathway the coefﬁcient of variance (CV) among the
compound pathway response scores. Because we were only
interested in responding pathways, we preselected pathways
with a positive average relative score meaning that the
pathway’s response score is higher compared with the median
pathway score on average. With that procedure, we identiﬁed
72 pathways ‘‘consistently affected’’ (CV < 0.5) by GTX
compounds, 45 pathways ‘‘consistently affected’’ by NGTX
compounds, and 35 by NC compounds. Among these,
‘‘consistently affected’’ NGTX pathways were, for example,
PPAR signaling (CV ¼ 0.383), glycolysis (CV ¼ 0.258), and
mTOR signaling (CV ¼ 0.309) pointing to important human
in vivo processes of carcinogenesis. An illustrative example of
the gene-wise contributions to the pathway scoring is given
with the PPAR signaling pathway (Fig. 3C).
Thirdly, extrapolating gene expression information to the
pathway level improved the discrimination of the toxicity
classes. We have performed a similar ANOVA approach as for
TABLE 2
Cross-Validation Performance
Experiments n
Whole genome
(N ¼ 18,394)
Response genes
(N ¼ 592)
Misclassiﬁcation
rate ±
Misclassiﬁcation
rate ±
24-h exposure 24 20.83 8.47 20.83 8.47
72-h exposure 24 20.83 8.47 4.17 4.17
IC 10/2 concentration 18 27.78 1.86 16.67 9.04
IC 10 concentration 30 26.67 8.21 1.33 6.31
All experiments 48 6.25 3.53 4.17 2.92
TABLE 1
Overrepresentation of Pathways with Respect to the 592 Response Genes
Pathway
Genes in
pathway
Overlap with
response genes p Value (Fisher) Source database Response genes in pathway
Wnt lrp6 signaling 7 (7) 3 0.00349 BioCarta DKK1, FZD1, WNT8A
ATM signaling pathway 20 (18) 4 0.00991 BioCarta ATM, GA45A, MDM2, P73
Hop pathway in cardiac development 4 (4) 2 0.0134 BioCarta NKX25, SRF
Aurora A signaling 33 (31) 5 0.0161 PID GA45A, MDM2, MPIP2, OAZ1, RASA1
Stabilization of p53 5 (5) 2 0.0215 Reactome ATM, MDM2
Glycogen breakdown (glycogenolysis) 14 (14) 3 0.0281 Reactome GDE, PHKG1, PHKG2
Cysteine biosynthesis II 7 (6) 2 0.0313 HumanCyc SERA, SERB
CREB phosphorylation 7 (7) 2 0.0424 Reactome KS6A3, KS6A5
p53 signaling pathway 69 (68) 7 0.047 KEGG ATM, GA45A, MDM2, P73, PPM1D,
SESN1, TNR6
Branched-chain amino acid catabolism 18 (17) 3 0.0471 Reactome AUHM, HIBCH, ODBB
p53 signaling pathway 17 (17) 3 0.0471 BioCarta BCL2, GA45A, MDM2
284 YILDIRIMMAN ET AL.gene expression patterns with the pathway response patterns and
were able to achieve a complete separation of the 15 compounds
into 3 distinct groups with a subset of 37 pathways (Fig. 3D).
Compared with the grouping achieved on the gene level (cf.
Fig. 2A), the pathway level shows an increase in performance.
Genotoxic Responses in hES-Hep—Benzo[a]pyrene Case Study
Because we measured a strong overall signal from cancer-
related pathways (see above), we were interested whether the
hES-Hep system reproduces genotoxic responses known from
(rodent) in vivo studies and investigated exemplary the effects
of BAP treatment, which is one of the best studied genotoxic
carcinogens. BAP is of particular interest because it requires
metabolic transformation for exerting its genotoxic effects
through BAP diolepoxide by several cytochrome P450
enzymes and, thus, challenges the metabolic competence of
the cell system. Upon BAP treatment, we observed upregula-
tion of cytochrome P450 enzymes CYP1A1 (p ¼ 0.006, fold
change ¼ 3.57) and CYP1B1 (p ¼ 0.0004, fold change ¼ 6.30)
judging the three BAP treatment and control replicates with
Student’s t-test. CYP1A1 and CYP1B1 display similar catalytic
activities in converting B[a]P-7,8-dihydrodiol to mutagenic
metabolites (Chen et al., 2003). Upregulation of these CYPsi s
through binding of BAP to AHR, a ligand-activated nuclear
transcription factor (Hockley et al.,2 0 0 7 ; Nebert et al., 2004).
AHR was also found upregulated in hES-Hep (p ¼ 0.002, fold
change ¼ 1.93). In total, 673 genes were differentially
regulated upon BAP treatment (p value < 0.01). These genes
monitored carcinogenic response at the interplay of apoptosis
(IRAK1/2, BIRC3, FAS, PIK3R2, TNFRSF10D, and IL1B), p53
signaling (FAS, NOXA, RRM2B, PPM1D, DDB2, SESN1/2,
PIDD, YWAS, GADD45A, and RIR2B), and DNA damage
pathways.
At the pathway level (cf. previous section), the highest
response scores to BAP exposure were observed for modules
of the apoptosis pathway in particular its induction by FAS
ligand and caspase activation (CASP8). Fourteen pathways had
a highly elevated pathway score, seven of which were
associated with apoptosis (Supplementary table 4). This strong
apoptotic response in the human cells reproduced previous
ﬁndings, for example, in rat liver epithelial cell lines (Huc
et al., 2006). Furthermore, we performed Student’s t-test with
the pathway response scores and compared all carcinogenic
treatments (GTX and NGTX) with the noncarcinogenic
treatments (NC). It can be seen in Supplementary table 4 that
the apoptotic response observed in BAP-treated cells was fairly
stable among other carcinogenic treatments as well, for
example, for ‘‘FasL/CD95L signaling’’ (p ¼ 0.085), ‘‘sodd/
tnfr1 signaling pathway’’ (p ¼ 0.045), and ‘‘death receptor
signaling’’ (p ¼ 0.054).
DISCUSSION
In this study, we have used an in vitro model based on hESC
differentiated to hepatocyte-like cells (hES-Hep). It has been
previously published by us and others that such cells show
similarities as well as differences, depending on the differen-
tiation protocol, compared with HepG2 and different fetal and
adult liver samples. hES-Hep were studied at day 22 after onset
of differentiation when the cells show an attractive hepatic
TABLE 3
Correlation of Expression Patterns of Response Genes in Liver-Like Systems
A
hES-Hep Adult liver Fetal liver HepG2 Nonplated PHH Plated PHH
hES-Hep 1 0.7866 0.8049 0.8300 0.7648 0.8790
Adult liver 0.7866 1 0.8967 0.7493 0.9796 0.9084
Fetal liver 0.8049 0.8967 1 0.7910 0.8798 0.8728
HepG2 0.8300 0.7493 0.7910 1 0.7524 0.8442
Nonplated PHH 0.7648 0.9796 0.8798 0.7524 1 0.9028
Plated PHH 0.8790 0.9084 0.8728 0.8442 0.9028 1
B
GTX NGTX GSE29722
GTX 1.0000 0.9818 0.8040
NGTX 0.9818 1.0000 0.8237
GSE29722 0.8040 0.8237 1.0000
2NF 0.9867 0.9914 0.8099
AFL 0.9917 0.9823 0.8013
BAP 0.9935 0.9656 0.7924
CYC 0.9771 0.9292 0.7659
NNK 0.9924 0.9832 0.8036
MPH 0.9719 0.9941 0.8167
PPX 0.9748 0.9948 0.8140
SPB 0.9749 0.9950 0.8186
TPE 0.9783 0.9889 0.8137
WYE 0.9750 0.9921 0.8270
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and functional level (Fig. 1). hES-Hep, in general, express
higher levels of CYP expression as compared with HepG2 but
lower levels in comparison with hpHep, however, still
conﬁrming the metabolic competence of the system. An
interesting outcome of this study is that the correlation of
expression of the response genes in hES-Hep is mostly
correlated to that in plated hpHep among the ﬁve hepatic cell
models used (Table 3). It is worth mentioning, though, that
these data monitor the expression of hES-Hep in the untreated
state and, thus, give no evidence per se that either of the
models is a valid assay system for carcinogenicity hazard
prediction because each system can respond differently to
chemical treatment.
We challenged the hES-Hep model with a panel of 15
substances from three different toxicity classes. Although these
substances exerted different modes of action and different
strengths of effects, we were able to identify discriminative
classiﬁer sets on the gene (592 genes) and the pathway (37
pathways) levels. In particular, genotoxic substances induced
the largest effects in the cells. We exempliﬁed this with
benzo[a]pyrene, but similar results were obtained with other
GTX compounds. Strong pathway responses were observable
in DNA damage response, p53 signaling, and, in particular,
apoptosis. It is evident that the prediction of nongenotoxic
carcinogenic effects is far more difﬁcult compared with
genotoxic and, thus, that the hES-Hep model, as presumably
most in vitro models, has a prevalence for the identiﬁcation of
directly acting genotoxins. On the other hand, we observe clear
effects related to the hallmarks of cancer (Hanahan and
Weinberg, 2011) induced by nongenotoxic substances what
emphasizes the usefulness of the cellular model for prediction
of carcinogenicity. Additionally, hierarchical clustering of the
expression matrix derived from the 592 genes and the 15
treatment experiments (Supplementary ﬁgure 3A) revealed ﬁve
main clusters of genes (Supplementary ﬁgure 3B). Among
these, cluster 2 (C2, N ¼ 176) exhibited genes basically
unaffected by GTX treatments and predominantly upregulated
with NC and NGTX substances.
It has been emphasized that toxicity pathways leading to
carcinogenesis in humans are not yet fully characterized
(Cohen, 2010) and inherently different from those in rodents
(Ward, 2008). Carcinogenic effects induced in rodents by
speciﬁc compounds might thus not easily been extrapolated
to the human situation leading to a large amount of false
positive predictions. This is particularly true for the class of
nongenotoxic carcinogens that show a diversity of modes of
action, tissue and species speciﬁcity, and absence of genotox-
icity what makes predicting their carcinogenic potential
extremely challenging (Hernandez et al., 2009). For example,
FIG. 3. Pathway response analysis. (A) Response scores for apoptosis (top) and MAPK (bottom) pathways distinguishing carcinogenic from noncarcinogenic
treatments (red ¼ GTX, blue ¼ NGTX, and green ¼ NC). Y-axis shows relative response with respect to the median response in the respective treatment
experiment (log2 scale). (B) Response scores for FAS (top) and PPAR (bottom) distinguishing toxicity classes. (C) Illustration of pathway scoring with PPAR
signaling after WYE treatment. 61 genes (x-axis) were measured with microarrays. Bars (y-axis) show the log2 ratio of WYE treatment signals versus controls.
Bars are shadowed according to signiﬁcance of the fold changes when judging the three replicate measurements (dark ¼ signiﬁcant). Genes with signiﬁcant fold
change (p < 0.05) are displayed with an asterisk on top of the bar. The red circles display the gene score that was computed from the fold change and signiﬁcance
p values as described in ‘‘Materials and Methods.’’ The horizontal lines mark a 1.33 deregulation. (D) PCA derived from 37-pathway response patterns for the
15 substance treatments yields a perfect separation of the toxicity classes. Total variance explained is 69.5% (PC1: 49.9%; PC2: 19.6%).
hESC TECHNOLOGY FOR PREDICTING CARCINOGENICITY 287WYE and SPB are both compounds with clear carcinogenic
effects in rodents but with no consensus regarding the human
situation. In our pathway analysis, these compounds were
jointly highly responding to the BioCarta pathway ‘‘srebp
control of lipid biosynthesis’’, among others, which potentially
links their expression responses to human cancer. It has been
shown that several steps in lipid synthesis promote tumor
development, for example, through involvement of mTOR
signaling (Hsu and Sabatini, 2008; Laplante and Sabatini, 2009).
Statistical classiﬁcation is the standard way of judging the
quality of a hazard assessment assay, however, the panel of
substances must be enlarged for such an approach. Although
there is a considerable risk of overﬁtting the data because of the
small number of compounds, our results serve as a proof of
principle demonstrating that toxicity classes can be discrimi-
nated with the hES-Hep system with high conﬁdence (Table 2).
An alternative to the statistical approach would consist in the
development of discriminative mechanisms based on prese-
lected genes. We have shown evidence that the identiﬁed
response gene set exhibits multiple carcinogenic effects and
even increases cross-validation performance compared with the
genome-wide approach.
Furthermore, following-up the discriminating pathways will
stimulate future mechanistic approaches. Pathway scoring
(Fig. 3C) increases the performance of compound discrimination
as can be seen by comparing Figures 2A and 3D. This increase
of performance is effected by the pregrouping of expression
patterns that copes better with the inherent variation of gene
expression measurements and conﬁrms previous similar ﬁnd-
ings, for example, in the context of disease classiﬁcation (Lee
et al.,2 0 0 8 ). We have shown that different pathway modules
could be associated with individual chemicals and toxicity
classes. These pathway modules were highly discriminative, and
they were linked to carcinogenesis comprising, for example,
apoptosis (p ¼ 0.0065), MAPK (p ¼ 0.0013), and PPAR (p ¼
0.0157) signaling. The role of PPAR signaling for rodent
carcinogenesis is evident due to the fact that PPAR-a activation
leads to increased proliferation, decreased apoptosis, and
activation of reactive oxygen species leading to hepatocellular
carcinoma as a long-term response, whereas in human, this
effect has not been proven so far (Michalik et al.,2 0 0 4 ). On the
other hand, non–DNA reactive mechanisms, such as production
of active oxygen species and lipid peroxidation that are
inﬂuenced by PPAR signaling, can induce genotoxicity in
humans by secondary effects (Ellinger-Ziegelbauer et al.,2 0 0 9 ).
We also checked the consistency of expression of the
response genes within each toxicity class with a one-sample
Student’s t-test. 421 (of 592) genes were identiﬁed as
consistently differentially expressed (Supplementary ﬁgure 4).
These genes indicate potential mechanisms of carcinogenesis,
for example, FBXW7, a known tumor suppressor whose
activation could be interpreted as a cell protection mechanism,
TAP1 that was related to E2F and the apoptosis pathway in
HepG2 liver cells (Li et al., 2010), TRIAP1 that was related to
p53 signaling (Felix et al., 2009; Park and Nakamura, 2005), or
CXCL10 that was related to prolonged tumor growth delay in
CT26 and 4T1 tumor models (Wang et al., 2010). Furthermore,
301 (of 592) genes were selectively altered within a speciﬁc
toxicity class; of these, 153 (51%) were speciﬁc for GTX, 60
(20%) for NGTX, and 88 (29%) for NC substances. These
genes build a rich basis for extrapolation of further mechanistic
information and ultimately, a mechanistic response model, for
chemical carcinogenesis in the hES-Hep model.
To summarize, we have demonstrated that hESC technology
has high potential for developing in vitro hazard assessment
assays for carcinogenicity of chemicals as was shown with
three representative toxicity classes. We have quantiﬁed and
identiﬁed discriminative carcinogenic pathway responses based
on modules of the apoptosis, MAPK, and p53 signaling
pathways that build the basis for a mechanistic understanding
of chemical carcinogenesis. Although the hES-Hep model
needs further reﬁnement and, additional challenges with more
compounds, in order to meet a broader acceptance, this study
paves the way toward use of stem cell–derived liver cells for
toxicity testing. In the future, this may lead to less use of
animal experiments and increased possibilities to avoid
bringing harmful chemicals to the market.
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